IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
InfuSystem Holdings, Inc. (INFU) is a leading provider of infusion pumps and related products and services in the United States and Canada, primarily serving the oncology and pain management markets.
Investment Thesis
INFU is a direct play on the 'hospital to home' transition in healthcare. As insurers and patients look to lower costs, treatments that were once performed in expensive hospital settings (like chemotherapy) are increasingly moving to the home. InfuSystem owns and manages the fleet of pumps required for these treatments. Their model is highly recurring: they rent the pumps and sell the high-margin consumable tubing and medication bags required for every dose. With a dominant market share in the oncology market and a growing footprint in wound care and pain management, INFU is a high-margin service provider with a massive demographic tailwind.
Key Growth Drivers
Home Healthcare Transformation
The structural shift toward home-based infusion therapy provides InfuSystem with a steady and growing pipeline of new patients.
Oncology Market Leadership
INFU is the 'de facto' partner for oncology clinics nationwide, creating a powerful barrier to entry for any potential competitors.
Consumable Revenue Growth
The sale of high-margin single-use disposables associated with every pump rental drives consistent organic revenue growth and margin expansion.
Valuation & Financial Modeling
INFU trades at a reasonable multiple relative to its recurring revenue and the growth of its new product lines. We believe the market is underestimating the strategic value of its nationwide logistics and maintenance network for medical pumps.
Risk Factors & Bear Case
Changes in Medicare reimbursement rates for infusion services are the primary risk. Additionally, any supply chain disruption for infusion pumps or specialized consumables would hit near-term revenue.
Conclusion
InfuSystem is a high-quality play on the efficiency of the U.S. healthcare system. It offers stable, defensive growth at a reasonable price. Rated 'Buy'.
Upcoming Catalysts
No upcoming catalysts identified.
Unlock Investment Thesis
Sign up for free access to institutional-quality research tools.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 50GRADE C+
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
11.2%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, InfuSystem Holdings, Inc (INFU) receives a "Hold" rating with a composite score of 51.2/100, ranked #470 out of 4446 stocks. Key factor scores: Quality 50/100, Value 66/100, Momentum 55/100. This is quantitative analysis only — not investment advice.
InfuSystem Holdings, Inc (INFU) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does InfuSystem Holdings, Inc Do?
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan. InfuSystem Holdings, Inc (INFU) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Richard A. Dilorio and employs approximately 410 people, headquartered in MADISON HEIGHTS, Michigan. With a market capitalization of $188M, INFU is one of the notable companies in the Healthcare sector.
InfuSystem Holdings, Inc (INFU) Stock Rating — Hold (April 2026)
As of April 2026, InfuSystem Holdings, Inc receives a Hold rating with a composite score of 51.2/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.INFU ranks #470 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, InfuSystem Holdings, Inc ranks #24 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
INFU Stock Price and 52-Week Range
InfuSystem Holdings, Inc (INFU) currently trades at $9.38. The stock lost $0.24 (2.5%) in the most recent trading session. The 52-week high for INFU is $11.04, which means the stock is currently trading -15.0% from its annual peak. The 52-week low is $4.61, putting the stock 103.5% above its annual trough. Recent trading volume was 60K shares, suggesting relatively thin trading activity.
Is INFU Overvalued or Undervalued? — Valuation Analysis
InfuSystem Holdings, Inc (INFU) carries a value factor score of 66/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 29.92x, compared to the Healthcare sector average of 23.63x — a premium of 27%. The price-to-book ratio stands at 3.34x, versus the sector average of 2.75x. The price-to-sales ratio is 1.34x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, INFU trades at 8.59x EV/EBITDA, versus 6.34x for the sector.
Overall, INFU's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
InfuSystem Holdings, Inc Profitability — ROE, Margins, and Quality Score
InfuSystem Holdings, Inc (INFU) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 11.2%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 6.4% versus the sector average of -33.1%.
On a margin basis, InfuSystem Holdings, Inc reports gross margins of 55.3%, compared to 71.5% for the sector. The operating margin is 8.0% (sector: -66.1%). Net profit margin stands at 4.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 8.3% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
INFU Debt, Balance Sheet, and Financial Health
InfuSystem Holdings, Inc has a debt-to-equity ratio of 34.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 1.80x, suggesting adequate working capital coverage. Total debt on the balance sheet is $20M. Cash and equivalents stand at $955,000.
INFU has a beta of 1.46, meaning it is more volatile than the broader market — a $10,000 investment in INFU would be expected to move 45.8% more than the S&P 500 on any given day. The stability factor score for InfuSystem Holdings, Inc is 53/100, reflecting average volatility within the normal range for its sector.
InfuSystem Holdings, Inc Revenue and Earnings History — Quarterly Trend
In TTM 2026, InfuSystem Holdings, Inc reported revenue of $143M and earnings per share (EPS) of $0.32. Net income for the quarter was $6M. Gross margin was 55.3%. Operating income came in at $11M.
In FY 2025, InfuSystem Holdings, Inc reported revenue of $143M and earnings per share (EPS) of $0.32. Net income for the quarter was $7M. Gross margin was 56.0%. Revenue grew 6.4% year-over-year compared to FY 2024. Operating income came in at $12M.
In Q3 2025, InfuSystem Holdings, Inc reported revenue of $36M and earnings per share (EPS) of $0.11. Net income for the quarter was $2M. Gross margin was 57.1%. Revenue grew 3.3% year-over-year compared to Q3 2024. Operating income came in at $4M.
In Q2 2025, InfuSystem Holdings, Inc reported revenue of $36M and earnings per share (EPS) of $0.12. Net income for the quarter was $3M. Gross margin was 55.2%. Revenue grew 6.8% year-over-year compared to Q2 2024. Operating income came in at $4M.
Over the past 8 quarters, InfuSystem Holdings, Inc has demonstrated a growth trajectory, with revenue expanding from $34M to $143M. Investors analyzing INFU stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
INFU Dividend Yield and Income Analysis
InfuSystem Holdings, Inc (INFU) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
INFU Momentum and Technical Analysis Profile
InfuSystem Holdings, Inc (INFU) has a momentum factor score of 55/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 30/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 42/100 reflects moderate short selling activity.
INFU vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing INFU against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INFU vs S&P 500 (SPY) comparison to assess how InfuSystem Holdings, Inc stacks up against the broader market across all factor dimensions.
INFU Next Earnings Date
No upcoming earnings date has been announced for InfuSystem Holdings, Inc (INFU) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy INFU? — Investment Thesis Summary
InfuSystem Holdings, Inc presents a balanced picture with arguments on both sides. The value score of 66/100 suggests attractive pricing relative to fundamentals.
In summary, InfuSystem Holdings, Inc (INFU) earns a Hold rating with a composite score of 51.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INFU stock.
We'll email you when stocks you follow change their composite rating.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
8.3%
Sector: 10.6%
-22% VS SCTR
Gross Margin
Core pricing power
55.3%
Sector: 71.5%
-23% VS SCTR
Operating Margin
Operating efficiency
8.0%
Sector: -66.1%
-112% VS SCTR
Net Margin
Bottom-line conversion
4.4%
Sector: -58.7%
-108% VS SCTR
Return on Equity
Equity capital efficiency
11.2%
Sector: -43.5%
-126% VS SCTR
Return on Assets
Asset base utilization
6.4%
Sector: -33.1%
-119% VS SCTR
Debt/Equity
Financial leverage load
34.0%
Sector: 32.0%
IN LINE
Dividend Yield
Direct cash return
0.0%
Sector: 0.0%
-NaN% VS SCTR
+21%
Price / Sales
1.3x
-19%
InfuSystem Holdings, Inc exhibits a 16% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
6.4%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
55.3%
Sector: 71.5%
Operating Margin
Core business profitability
8.0%
Sector: -66.1%
Net Margin
Bottom-line profitability
4.4%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.